New York, June 16, 2026, 07:03 (ET)
- IVDA finished Monday at $0.3162, up 12.57%. Early Tuesday, Google Finance was showing pre-market levels close to $0.48.
- Iveda launched an updated version of its IvedaRTLS asset-tracking tool for hospitals, manufacturers and logistics firms. That followed the earlier rollout.
- Iveda keeps posting losses and remains a speculative bet, while Nasdaq has given a $1 minimum bid-price deadline of September 2, 2026.
Iveda Solutions, Inc. jumped Monday after announcing its new precision-tracking feature. The Mesa, Arizona tech firm finished the session at $0.3162, up 12.57%. Traders came back into the Nasdaq small-cap, with volume spiking. Google Finance reported nearly 59.6 million shares changed hands; Robinhood put the total above 61 million, both far ahead of normal. On Tuesday before the open, Google Finance showed quotes near $0.48. Google
Iveda shares reacted after the company announced June 15 an upgrade to its IvedaRTLS platform, which tracks assets and personnel using tags, anchors and dashboard software. The new version brings in Bluetooth Angle of Arrival tech, letting the system estimate positions by measuring where signals come from, with up to 10 centimeter accuracy. Iveda said it’s going after hospitals, manufacturers and logistics groups who want tighter asset tracking and less equipment loss. “This upgrade closes the gap, giving organizations visibility precise enough to make appropriate decisions immediately,” CEO and founder David Ly said. Business Wire
Iveda shares are quick to swing on headlines, with traders often jumping in on any news about possible sales because of the company’s small market value. This time, though, the latest release didn’t show a contract value or any fresh customer order, so the market is left wondering if there’s real business behind it or just hype. Investing.com pointed to the RTLS product upgrade as the driver for the move and also called out Iveda’s cheap valuation and weak stock action over the past year.
Iveda is targeting practical problems like tracking hospital equipment, with tools aimed at customers looking for AI and automation, bulls say. The company reported $1.49 million in revenue last quarter, a slight rise from $1.47 million a year earlier, its latest 10-Q shows. Gross profit was $495,208, up from $288,211 in the same period last year. Iveda ended the quarter with $5.63 million in cash and equivalents as of March 31, which boosts its balance sheet.
Bearish risks still hang over Iveda. The company posted a net loss of $532,831 for the March quarter, burning through $927,120 in operating cash. That means Iveda’s main business is eating up cash. Shares ballooned to 11.59 million, up from 5.88 million at year end, after the company sold more common stock, diluting existing shareholders. Iveda also trades under Nasdaq’s $1 minimum. In a March 8-K, the company said it has until September 2, 2026, to regain compliance by trading at or above $1 for 10 consecutive business days.
Investors are waiting to see if the RTLS upgrade brings in real signed contracts instead of just heavier trading. Next, the company reports earnings, with Public putting the IPO date at August 13, 2026. September sets the deadline for Nasdaq’s minimum bid price. IVDA is still a high-risk, speculative name. Product quality has improved, but the stock is hard to value with low revenue, steady losses, and ongoing Nasdaq compliance issues.
